Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
MWN-AI** Summary
Terumo Interventional Systems (TIS), a division of Terumo Corporation, has received FDA 510(k) clearance for its innovative OPUSWAVE® Dual Sensor Imaging System, featuring the DualView® imaging catheter. This groundbreaking system integrates Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to provide simultaneous imaging capabilities, which can significantly enhance the evaluation and treatment of coronary artery disease (CAD).
The DualView imaging catheter, a key component of the OPUSWAVE system, boasts a maximum pullback length of 150mm and an imaging profile of just 2.6 Fr., ensuring high compatibility with standard 6 Fr. guides. It also features a versatile pullback speed of up to 40mm per second in dual mode, enabling physicians to tailor the imaging process to specific patient needs. This advanced technology not only enhances imaging efficiency but also holds the potential to reduce procedural times and associated costs.
Dr. Ghada Farah, President of Terumo Interventional Systems, emphasized that the OPUSWAVE Imaging System allows clinicians to create comprehensive treatment plans with improved imaging quality. She stated that the combined capabilities of OFDI and IVUS in a single catheter present an unprecedented opportunity for cardiologists performing percutaneous coronary interventions (PCI).
Dr. Michael J. Martinelli, Chief Medical Officer of Terumo Medical Corporation, highlighted that the OPUSWAVE system provides flexibility for physicians, allowing them to utilize the benefits of both imaging modalities when assessing and treating lesions of varying morphologies.
As TIS expands its impact in the U.S. market, it leverages its established leadership in single modality imaging within Japan, where PCI imaging is particularly advanced. Terumo's commitment to innovation in minimally invasive medical solutions continues to drive improvements in patient care across global healthcare landscapes.
MWN-AI** Analysis
Terumo Interventional Systems' recent announcement regarding the FDA 510(k) clearance for its OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter signals a significant advancement in interventional cardiology. By merging Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) within a single catheter, Terumo is positioned to enhance procedural efficiency and patient outcomes in coronary artery disease (CAD) treatment. This innovative approach could potentially reshape the imaging landscape in percutaneous coronary interventions (PCI).
Investors should view this development with cautious optimism, considering several factors. The dual modalities allow for comprehensive lesion evaluations, which can substantially shorten procedure times and reduce costs. As the imaging market in PCI grows, driven by rising CAD incidences, Terumo’s entry could capture market share from existing technologies. The combination of features such as a 150mm maximum pullback length, 2.6 Fr. imaging profile, and high compatibility with various guide configurations adds to the system's appeal to interventional cardiologists.
Furthermore, Terumo’s long-standing reputation in Japan provides a solid foundation for successful market penetration in the United States, where single-modality imaging is currently prevalent. The company's strategic initiatives in advanced treatment solutions may catalyze future growth.
However, potential investors should evaluate competition from established players in the interventional imaging field, who may respond to this innovation with enhancements to their product lines. Additionally, it is critical to monitor adoption rates and the overall impact of healthcare policies on medical device reimbursement.
In summary, Terumo’s OPUSWAVE Imaging System represents a promising opportunity in a growing market. Investors should keep an eye on the adaptation trajectory and performance metrics post-launch to assess Terumo's potential in delivering sustained growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease
- DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibility and a variable pullback speed of up to 40mm/second in dual mode
SOMERSET, N.J., Oct. 24, 2025 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE® Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView® imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE Imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world.
"Importantly, the OPUSWAVE Imaging System allows physicians to maximize imaging efficiency without sacrificing quality when it comes to creating treatment plans to achieve the best outcomes for their patients," said Ghada Farah, President, Terumo Interventional Systems. "By combining the advanced imaging capabilities of OFDI and IVUS into a single catheter, the OPUSWAVE Imaging System also creates a strong opportunity to shorten procedural time and costs in treating CAD."
What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.
"The OPUSWAVE Imaging System is an ideal technology for interventional cardiologists who perform image-guided PCI," said Michael J. Martinelli, MD, FACC, FSCAI and Chief Medical Officer, Terumo Medical Corporation. "This innovative imaging system provides the opportunity for physicians to take advantage of the benefits of both OFDI and IVUS in the assessment and treatment of any lesion morphology. Instead of having to commit to one imaging tool, they now have the flexibility to access both imaging modalities with a single catheter."
About Terumo Interventional Systems
Terumo Interventional Systems (TIS), a division of Terumo Corporation, is a market leader in minimally invasive entry site management, lesion access, and therapeutic intervention. TIS offers a complete, solution-based product portfolio used in advanced coronary, peripheral and endovascular treatments with strategic initiatives in Transradial Access, Complex Coronary Intervention, Peripheral Artery Disease and Embolotherapy. TIS combines innovative research and development with a deep market understanding to create a pipeline of industry-leading devices that deliver clinical value, economic benefit, and enhanced patient outcomes. More information can be found at www.terumois.com.
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. More information can be found at www.terumo.com.
SOURCE Terumo Interventional Systems
FAQ**
How does the OPUSWAVE Imaging System from Terumo Corporation ADR TRUMY integrate OFDI and IVUS to enhance efficiency in coronary artery disease procedures compared to traditional imaging methods?
With the OPUSWAVE Imaging System now receiving FDA 510(k) clearance, what strategic advantages could Terumo Corporation ADR TRUMY leverage in the competitive medical imaging market in the U.S.?
What potential impact do you foresee on procedural costs and time for interventional cardiologists using the OPUSWAVE Imaging System from Terumo Corporation ADR TRUMY, given its unique DualView imaging catheter capabilities?
As Terumo Corporation ADR TRUMY transitions from Japan's imaging market to the U.S., what challenges and opportunities might arise in the adoption of the OPUSWAVE Imaging System among healthcare providers?
**MWN-AI FAQ is based on asking OpenAI questions about Terumo Corporation ADR (OTC: TRUMY).
NASDAQ: TRUMY
TRUMY Trading
1.01% G/L:
$13.04 Last:
43,678 Volume:
$12.6301 Open:
